EDGAR 10-K Filing

Company CIK: 1164888
Filing Year: 2021
Filename: 1164888_10-K_2021_0001078782-21-000715.json

---

ITEM 1. BUSINESS
ITEM 1. BUSINESS
(A) BUSINESS DEVELOPMENT
Kyto Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of B Twelve, Inc.. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc.. In July 2019, the Company was re-incorporated as a Delaware company. The Company operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.
The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.
The Company has one regular employee - the CEO. Prior to December 31, 2020 the chief executive officer, Paul Russo, of Kyto Technology and Life Science, Inc. was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. For the year ended March 31, 2021 he was granted 215,000 stock options, and an ex-gratia bonus of $210,000. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% is paid monthly, and the balance deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in an engagement letter filed on Form 8K on February 1, 2021, incorporated by reference herein, which was approved by the Compensation committee of the Board of Directors on that date.
The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $400,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.
At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c ) (1).
As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.
B) REPORTS TO SECURITY HOLDERS
The Bylaws of Kyto Technology and Life Science, Inc. are silent regarding an annual report to shareholders. Kyto Technology and Life Science, Inc. is a reporting company and files reports with the U.S. Securities and Exchange Commission (SEC). The Company is required to file quarterly reports (Form 10-Q) and an annual report (Form 10-K) with the SEC. The annual report includes audited financial statements.
Any materials that the Company filed with the Securities and Exchange Commission may be read and copied at the SEC's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. Further, you may obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SECD-0330. The Company is an electronic filer and the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Commission. That site is http://www.sec.gov.

---

ITEM 1A. RISK FACTORS

---

ITEM 1B. UNRESOLVED STAFF COMMENTS

---

ITEM 2. PROPERTIES
ITEM 2. DESCRIPTION OF PROPERTY
The Company operates its business virtually from third party premises, or the homes of its directors and officers.

---

ITEM 3. LEGAL PROCEEDINGS
ITEM 3. LEGAL PROCEEDINGS
There is no litigation of any type whatsoever pending or threatened by or against the Company, its officers and directors.

---

ITEM 4. MINE SAFETY DISCLOSURE
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable
PART II

---

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The following discussions should be read in conjunction with the financial statements and related notes which are included in this Form 10-K for the year ended March 31, 2021. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to find and realize gains on our investments.
(A) MARKET INFORMATION
As of February 23, 2011, our stock quotation coverage moved from the FINRA operated OTC Bulletin Board to the OTC Markets Group, Inc.'s OTCQB under the same symbol "KBPH."
Our common stock has traded on the OTC Bulletin Board (R), or OTCBB, since August 4, 2005. The Company's common stock is quoted on the Electronic Bulletin Board of the OTC market, under the trading symbol KBPH. The following table sets forth, for the calendar quarters indicated, the high and low closing prices for our common stock as reported by OTCBB for fiscal years ended March 31, 2020 and 2021. The quotations reflect inter-dealer prices, without retail mark-up, mark-down, or commission and may not represent actual transactions. The market for the common stock has been sporadic and there have been long periods during which there were few, if any, transactions in the common stock and no reported quotations. Accordingly, reliance should not be placed on the quotes listed below, as the trades and depth of the market may be limited, and therefore, such quotes may not be a true indication of the current market value of the Company's common stock.
Common Stock
Fiscal Year Ended March 31, 2021
High
Low
First quarter
$
2.30
$
2.00
Second quarter
$
2.00
$
1.75
Third quarter
$
2.00
$
2.00
Fourth quarter
$
2.00
$
1.90
Common Stock
Fiscal Year Ended March 31, 2020
High
Low
First quarter
*
*
Second quarter
*
*
Third quarter
*
*
Fourth quarter
$
2.25
$
2.05
* There were no trades in these periods
There were 9,983,082 shares of common stock outstanding as of the end of the fiscal year ended March 31, 2021.
(B) HOLDERS
According to information provided to us by the transfer agent for our shares of Common Stock, as of March 31, 2021, there were 14 holders of record of the shares of Common Stock, including depositories. Based upon information we have received from some of these record owners, we believe there are less than 100 beneficial holders of our shares of Common Stock.
(C) DIVIDENDS
The Company has not paid any dividends to date and has no plans to do so in the foreseeable future.
For so long as the Class A Preferred Stock remains outstanding, the Corporation shall not declare, set apart or pay any dividend, whether in cash or other property (other than dividends payable in shares of Junior Stock), upon any Common Stock of the Corporation or any other stock ranking with respect to dividends or on liquidation junior to the Class A Preferred Stock unless the holders of the Class A Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Class A Preferred Stock.
The holders of Class B Preferred Stock shall be entitled to receive out of any funds of the Corporation at a time legally available for the declaration of dividends, dividends at a cumulative rate of 10% under such terms and conditions as the Board shall prescribe, provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Class B Preferred Stock shall be payable before any dividends shall be declared or paid upon or set apart for the Common Stock.
(D) SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS.
The Company believes it is in its best interest to create and use incentive stock option plans to assist in recruiting, motivating and compensating advisors, consultants, directors and employees, and generally minimize the need for cash compensation.
In March 2018, the majority of the shareholders approved the introduction of the Kyto Technology and Life Science, Inc. 2018 Incentive Stock Option Plan and reserved a pool of 2,697,085 shares of common stock for issuance under this plan.
In July 2019, the majority of the shareholders of the Company approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“Plan”), and the Company reserved 2 million shares of common stock for issuance to directors, officers, consultants and advisors.
In December 2020, the majority of the shareholders of the Company approved the introduction of the Kyto Technology and Life Science 2020 Stock Option and Incentive Plan (“Plan”), and reserved 2 million shares of common stock for issuance to directors, officers, consultants and advisors.

---

ITEM 6. SELECTED FINANCIAL DATA
ITEM 6. SELECTED FINANCIAL DATA
Net change in net assets resulting from operations per common share for each of the
fiscal years shown below are based on the weighted average number of shares outstanding.
March 31,
March 31,
Net change in net assets resulting from operations
$
427,066
$
(773,399)
Net change in net assets resulting from operations per common share
$
0.06
$
(0.13)
Total assets
$
8,429,166
$
2,699,755
Total liabilities
$
1,436,003
$
32,144
Year ended March 31,
Statement of operations data
Investment income
Fee and other income
$
-
$
14,150
Total investment income
-
$
14,150
Operating expenses
Banking and professional fees
225,378
47,826
Other operating expenses
543,464
678,677
Total operating expenses
768,842
726,503
Net change in unrealized gain (loss) on investments
$
1,195,908
$
(61,046)
Net increase (decrease) in net assets resulting from operations
$
427,066
$
(773,399)
As of March 31
Balance sheet data
Net assets
$
6,993,163
$
2,667,611
Number of portfolio companies

---

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATION
(A) PLAN OF OPERATION
The Company made forty-seven investments in the year ended on March 31, 2021. These consisted of twenty-three investments in new portfolio companies totaling $1,784,997 and twenty-four follow-on investments into existing portfolio companies totalling $1,175,003.
The Company expects to continue raising funds to cover operating expenses and to continue new portfolio and follow-on investments in existing portfolio companies on an ongoing basis as it continues efforts to become effective as a “1940 Act” investment company. Once effective, the Company plans to engage an investment banker and list on the NASDAQ exchange.
(B) RESULTS OF OPERATIONS
Revenue: The Company depends on the emergence of liquidity situations to realize its investments in portfolio companies but does not have any ability to influence such events. During the years ended March 31, 2021 and 2020 there were no liquidation transactions and, accordingly the Company did not generate any proceeds from investments. However, the Company does regularly revalue its investments to ensure that they are stated at fair value and for the years ended March 31, 2021 and 2020, recognized unrealized valuation gains and losses of $1,195,908 and $(61,406), respectively.
Banking and professional fees: The Company incurred banking and professional fees of $225,378 and $47,826 for the years ended March 31, 2021 and 2020, respectively. The increase of 371% was largely attributable to increased legal fees in connection with fundraising transactions and the filing of a Form N-2 with the SEC in anticipation of our registration as a Business Development Corporation (“BDC”) and future uplisting from the OTC to Nasdaq stock market exchanges.
Other operating expenses: The Company incurred operating expenses of $543,464 and $678,677 in the years ended March 31, 2021 and 2020, respectively. The decrease of 20% reflects a reduction in investor relations expenses during the year ended March 31, 2021.
The Company did not experience any management fees or interest expense in either years.
For the years ended March 31, 2021 and 2020, the Company’s net increase or decrease in net assets resulting from operations was $427,066 and $(773,399), respectively.
(C) LIQUIDITY
The accompanying financial statements have been prepared assuming that we will continue as a going concern. We have experienced recurring negative cash flows from operations resulting in a deficit of $33.0 million accumulated from inception through March 31, 2021.
As of the date of this filing, the Company had approximately $400,000 of cash to cover its operating expenses and new investment requirements, and is continuing its efforts to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.
At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements.
As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.
The Company expects to continue raising funds to cover operating expenses and to continue new portfolio and follow-on investments in existing portfolio companies on an ongoing basis as it continues efforts to become effective as a “40 Act” investment company. Once effective, the Company plans to engage an investment banker and list on the NASDAQ exchange. To continue to fund operations, we will need to raise additional capital. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings, or other means. We may not be able to raise such additional capital on terms acceptable to us, if at all, and if there were any failure to raise capital when needed, or on attractive terms, we could be forced to reduce, delay or eliminate our investment activities or make reductions in spending, extend payment terms with suppliers, or liquidate or grant rights to our assets where possible. Any of these activities could materially harm our business, results of operations, or future prospects. There is no assurance that we can ever be profitable or generate sufficient cash flow from investment activities.
Cash from operating activities:
The Company’s net cash outflow from operations for the years ended March 31, 2021 and 2020 was $2,470,600 and $1,929,879 respectively, of which $2,960,000 and $1,228,497, respectively, resulted from the purchase of investments.
Cash from investing activities:
The Company did not have any cash flow from investing activities for the years ended March 31, 2021 and 2020.
Cash from financing activities:
The Company’s net cash inflow from financing activities for the years ended March 31, 2021 and 2020 was $3,874,712 and $1,870,001, respectively. During the year ended March 31, 2021, the Company raised from accredited investors $2,302,500 from private placements of Series B Preferred stock, and $1,572,212 from the sale of common stock in connection with the exercise of warrants and options. During the year ended March 31, 2020, the Company raised from accredited investors $1,270,001 from the sale of Series A Preferred stock and $600,000 from private placements of Series B Preferred stock.
(D ) SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments.
The Company’s financial statements are prepared using the specialized accounting principles of Accounting Standards Codification Topic 946, Financial Services-Investment Companies (ASC Topic 946). In accordance with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments. The Company carries its liabilities at amounts payable, net of unamortized premiums or discounts. The Company does not currently plan to elect to carry its liabilities at fair value. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.
The financial information associated with the March 31, 2021 and 2020 financial statements contains all adjustments and eliminations, consisting of only normal recurring adjustments, necessary for a fair presentation in accordance with GAAP.
REVENUE RECOGNITION
The Company generates realized gains or losses in its net assets from the sale of complete or partial investments following a mergers or acquisitions (“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in their value, either upwards or downwards. As a minority, early-stage investor, the Company does not have the ability to manage the timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a general guideline, it would expect such events to occur approximately four years after its investments are made. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized. The Company is in regular contact with the management of its portfolio investment companies to provide a basis for valuation changes or impairment reviews.
USE OF ESTIMATES
In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.
Significant estimates during the fiscal year ended March 31, 2021 and 2020 include the valuation of investments, stock options and warrants.
INVESTMENTS AND VALUATION OF INVESTMENTS AT FAIR VALUE
The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their current and future potential value and liquidity. In the event that Management considers the value of an investment to be impaired, the carrying value of the investment will be written down by an impairment charge to reflect Management’s estimated valuation. The Company recognized impairment of one of its investments which was written down by $61,046 in September 2019. The Company has not experienced any impairment write-downs in any prior or subsequent periods.
The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.
The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company will use observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company will use the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For investments for which quoted market prices are not available, which will comprise most of our investment portfolio, fair value will be estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.
In determining the appropriate fair value of an investment using these approaches, the most significant information and assumption may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, among other factors.
The estimated fair values will not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.
The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy are defined as follows:
Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. Most of the Company’s investments are Level 3.
Critical accounting policies and practices are the policies that are both most important to the portrayal of our financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. These include estimates of the fair value of our Level 3 investments and other estimates that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. Our estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 - Significant Accounting Policies” to our consolidated financial statements as of March 31, 2021 for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.
(E ) OFF-BALANCE SHEET ARRANGEMENT
None.

---

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

---

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Attached audited financial statements for Kyto Technology and Life Science, Inc. for the fiscal years ended March 31, 2021 and 2020 can be found beginning on page.

---

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
The Company did not change accountants during then year, however, subsequent to March 31, 2021, the Company’s current auditors, RBSM LLP resigned and OUM & Co. LLP was appointed as the Company’s independent registered public accounting firm. As of the date of these financial statements there are no disagreements with the findings of our accountants.

---

ITEM 9A. CONTROLS AND PROCEDURES
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer or Chief Financial Officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the year ended March 31, 2021 we carried out an evaluation, under the supervision and with the participation of our management, including the principal executive officer and the principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources, missed SEC filing deadlines, and limited number of employees, management concluded that our disclosure controls and procedures were ineffective as of March 31, 2021. Once the Company is listed on Nasdaq and raises additional funding from an IPO, management intend to increase the number of consulting or employee resources to provide more segregation of duties and supervision for an enhanced control environment.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of the financial statements of the Company in accordance with U.S. generally accepted accounting principles, or GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.
With the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2021 based on the framework in Internal Controls-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting as of March 31, 2021 based on the COSO framework criteria. Management has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software, and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly complex and/or unusual in nature. In such instances, we seek to augment our internal accounting capabilities by obtaining assistance from third-parties who have greater expertise in such areas.
These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness.
In light of this material weakness, we interviewed all accounting personnel to discover and evaluate our accounting and control procedures in order to conclude that our financial statements for the year ended March 31, 2021 included in this Annual Report on Form 10-K were fairly stated in accordance with US GAAP. Accordingly, management believes that despite our material weaknesses, our financial statements for the year ended March 31, 2021 are fairly stated, in all material respects, in accordance with US GAAP.
This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report on Form 10-K.
Limitations on Effectiveness of Controls and Procedures
Our management, including our Chief Executive Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Controls
During the fiscal year ended March 31, 2019, we engaged a third-party bookkeeping and accounting services to post accounting entries and reconcile our bank accounts. While this creates segregation of duties between the bookkeeping function and management supervision and control, we do not believe that these changes in our internal control over financial reporting should be regarded as material.

---

ITEM 9B. OTHER INFORMATION
ITEM 9B. OTHER INFORMATION.
We do not have any information required to be disclosed in a report on Form 8-K during the fourth quarter of fiscal 2021 that was not reported.
PART III

---

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT
(A) IDENTIFY DIRECTORS AND EXECUTIVE OFFICERS
Name
Age
Position
Michael Baghramian
Director (Appointed Jan 8, 2021)
Georges Benarroch
Director (Resigned April 5, 2021)
Paul Russo
Chief executive office and director
Jon S Saxe
Director (Appointed Jan 8, 2021)
Peter Staple
Director (Appointed Jan 8, 2021)
Simon Westbrook
Chief financial officer
The business experience of the persons listed above during the past five years are as follows:
MIKE BAGHRAMIAN, DIRECTOR
Mr. Baghramian has been President of Bager Electronics Inc. since 1980. Mr. Baghramaian has a great understanding of sales and marketing and was selected for that expertise. As the founder of Bager Electronics, a very successful semiconductor component rep firm covering the US South-West, his company supported sales of Dr. Russo’s three semiconductor start-ups, Genesis Microchip, Silicon Optix and Geo Semiconductor. Mr. Baghramian is semi-retired but remains active at Bager and sits on the boards of several charitable organizations; he will provide investment advice on potential Kyto investments, and his experience and expertise will be a valuable asset to the Board. He was appointed to the Board on January 8, 2021
GEORGES BENARROCH, DIRECTOR
Mr. Benarroch has been a director of the Company since May 5, 2000. He was elected as President and Chief Executive Officer effective February 27, 2006. Mr. Benarroch is the President and Chief Executive Officer of Comindus Finance Inc. Mr. Benarroch has over 40 years of investment banking as well as money management experience. Mr. Benarroch has raised financing for numerous companies, public as well as private, and has managed investment firms in the USA, Canada and Europe. Also, he has been the CEO of a Canadian multibillion dollar asset management firm. Mr. Benarroch resigned as President and Chief Executive Officer of KBPH on April 26, 2018 but remained as a Director. He resigned as a director of the Company on April 5, 2021.
MR. PAUL RUSSO, CHIEF EXECUTIVE OFFICER & DIRECTOR
Mr. Russo is the Co-founder and CEO of Kyto Technology and Life Science, Inc. He is also the Founder & Chairman of GEO Semiconductor (www.geosemi.com) since 2014, after having served as Chairman & CEO from its founding in 2008. Mr. Russo also serves as a Director of InBay (www.inbaytech.com), Irystec (www.irystec.com, Semplus (www.sempluscorp.com) and several other technology ventures (Peekaboo, Dynamount, Illuminati, Thrive, and other technology startups). Mr. Russo is heavily involved with the Band of Angels, the Keiretsu Forum and other similar organizations which review over 1,000 start-ups' business plans per year. He is also a Board Advisor to BWG, LLC. Mr. Russo served as an outside director of ATI Technologies from 2001 through its acquisition by AMD in 2006.
Prior to founding GEO Semiconductor, Mr. Russo founded Silicon Optix in 2000, a privately held fabless semiconductor company, serving as its Chairman & CEO through 2008. Prior to Silicon Optix, Mr. Russo was the founder, Chairman and CEO of Genesis Microchip (acquired by ST Micro in 2007) following Genesis Microchip’s NASD IPO in 1998.
Prior to founding Genesis, he was General Manager of the General Electric Microelectronics Center, Senior Manager of General Electric’s Industrial Electronics Development Lab and Head, Microsystems Research at RCA's David Sarnoff Research Center. While at RCA, Mr. Russo worked on the world first CMOS microprocessor and pioneered the first use of microprocessors in global communications, programmable video games, TV manufacturing automation and automotive engine control. Mr. Russo is a member of the Audit Committee, Nominating and Corporate Governance Committee, Investment Committee, and Compensation Committee.
JON S SAXE, DIRECTOR
Mr. Saxe has been a Life Science Advisor to the Company since August 2019. He has been Chairman of the Board of VistaGen Therapeutics since June 2000, Director of Arbor Vita Corporation since September 2000, Director of Arcuo Medical since January 2009, Director of Trellis Bioscience since June 2016, Chairman of Epalex Corporation since August 2017, Director of Cancer Prevention Pharmaceuticals, Inc. since October 2018, Director of Achelios since November 2019, Chairman of the Board of Aether Therapeutics since March 2020, Director of NuvOx Pharma since November 2020, Director of Lumos Pharma from 2010 to March 2020, Director of Armetheon from January 2013 to 2017, Director of Durect Corporation from 2003 to 2021, Director of SciClone Pharmaceuticals, Inc. from 2000 to 2017 and Chairman from 2009 to 2017. Mr. Saxe was selected to serve on the Board because of his extensive experience as a director, his involvement in the private equity and venture capital space, and his experience with biotechnology and pharmaceutical companies. Mr. Saxe has served on the board of directors of over 25 private and public companies and has served on audit, compensation, finance and governance committees. He also served as Vice President of Licensing and Corporate Development at Hoffmann-LaRoche, a large pharmaceutical company. Mr. Saxe is a registered patent attorney and brings extensive experience with intellectual property law to the Board and the Company’s portfolio companies. Mr. Saxe will be the lead non-interested Director. Mr. Saxe is a member of the Audit Committee, Nominating and Corporate Governance Committee, Investment Committee, and Compensation Committee.
PETER D STAPLE, DIRECTOR
Mr. Staple was most recently CEO and Director of Corium, Inc., a biopharmaceutical company from 2008-2019 and its Chairman and Director from 2019 until 2020. He is a Director of Corsair Pharma, Inc. from 2020 to the present and Assertio Therapeutics, Inc. since 2003. From 2002 to 2008, he served as Director, and from 2002 to November 2007 as Chief Executive Officer, of BioSeek, Inc., a privately-held drug discovery company. From 1994 to 2002, Mr. Staple was a member of the senior executive team at ALZA Corporation, where he was most recently Executive Vice President, Chief Administrative Officer and General Counsel. Prior to joining ALZA, he was Vice President, Associate General Counsel at two pioneering biotechnology companies: Chiron Corporation and Cetus Corporation. Mr. Staple holds a B.A. and a J.D. from Stanford University. The Board considered Mr. Staple’s expertise and experience in the following areas relevant to the Company and its business in concluding that he should serve on the Board: Executive management in multiple life-science based companies; corporate governance experience including service as a director, board chair and committee chair in public companies; corporate finance; legal strategies; and strategic transactions including mergers and acquisitions. Mr. Staple is a member of the Audit Committee, Nominating and Corporate Governance Committee, and Investment Committee.
MR. SIMON WESTBROOK, CHIEF FINANCIAL OFFICER
Effective March 15, 2018, Simon Westbrook was appointed the Company's Chief Financial Officer. In 2009, Mr. Westbrook founded Aargo Inc, a company specializing in financial consulting services to corporations in various tech-related industries. Prior to Aargo, Inc., Mr. Westbrook was CFO of Amber Networks, Inc., and the Chief Financial Officer of Sage, Inc. (NASDAQ: SAGI), a Silicon Valley company specializing in flat panel displays. Before joining Sage, Mr. Westbrook held a number of senior financial positions at Creative Technology (NASDAQ: CREAF), a leading PC multimedia company, and Atari Corp (AMEX: ATC), the video game and home computer company both in the USA and overseas. At various times, he has held positions as an advisory board member of the Silicon Valley Financial Executives Institute, and various technology start-up companies where he has assisted in strategic planning, fund raising and team development. Simon is a Chartered Accountant and holds a Masters in Economics from Trinity College, Cambridge in the UK.
(B) IDENTIFY SIGNIFICANT EMPLOYEES
John Ricci is a consultant to the Company and acts as Director, Portfolio Management. Mr. Ricci currently serves as managing director of US Angels (since 2003), co-founder of fundOn (since 2014), mentor at Alchemist Accelerator, Runway, Plug and Play Tech Center (since 2017), advisor and investor of App A Minute (since 2017), advisor and investor of EvoShare (since 2017), advisor of Linqto, Inc. (since 2015), advisor of 1World Online (2013). Mr. Ricci also has served as Managing Partner at MG Capital since 2009 and Founding and Managing Partner of Crimson Growth Partners LLP since 2013. Mr. Ricci graduated from MINES ParisTech and holds an MBA from Harvard Business School.
Richard Ayllon is a consultant to the Company and acts as Lead Manager, Due Diligence. Mr. Ayllon has served as an advisor of Stealth Start-Up - Surgical Robotics since February 2019. Mr. Ayllon is also the co-founder of Theravent, Inc. since October 2013. He previously served as the director of Strategic Marketing & New Business Development of Tria Beauty from July 2015 to May 2018. He has over 30 years of experience in leadership roles in life science organizations from multinational (Bayer, J&J) to early-stage/pre-revenue in multiple sectors/categories including pharmaceuticals, diagnostics, medical devices. Mr. Ayllon received his BSc from the University of Guelph (Guelph, Ontario, Canada and his MBA from the University of Western Ontario (London, Ontario, Canada).
Thomas Vogelsong is a consultant to the Company and acts as Director, Deal Flow. Mr. Vogelsong has been the Principal Consultant of Imaging Innovations, LLC since October 2015. Mr. Vogelsong is also an investor and advisor to early stage companies in the medical technology space, including InQCel, SV Advantage, Qanopy Group and RedCrow. Mr. Vogelsong provides technical expertise, as well as his business development and executive experience, to these companies. Mr. Vogelsong received his bachelor of science from Lehigh University and his M.S. and Ph.D. from Rensselaer Polytechnic Institute.
The Company does not currently have, nor expect to receive a significant contribution from, employees that are not executive officers.
(C) FAMILY RELATIONSHIPS
There are no directors, executive officers or persons nominated or persons chosen by the Company to become a director or executive officer of the Company who are directly related to an individual who currently holds the position of director or executive officer or is nominated to one of the said positions.
(D) INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS
There are no material events that have occurred in the last five years that would affect the evaluation of the ability or integrity of any director, person nominated to become a director, executive officer, promoter or control person of the Company.
(E) AUDIT COMMITTEE
The Company has formed an Audit Committee, Nominating and Corporate Governance Committee, Investment Committee, and Compensation Committees. The Board of Directors approved the financial statements for the previous year.

---

ITEM 11. EXECUTIVE COMPENSATION
ITEM 11. EXECUTIVE COMPENSATION
(A) SUMMARY COMPENSATION TABLE
The following table sets forth all annual and long-term compensation for services in all capacities rendered to Kyto by its executive officers and directors for each of the last two most recently completed fiscal years ended
Annual Compensation in $
Long-term compensation
awards in $
Payouts in $
Name and principal position
Year
ended
March 31,
Salary
Bonus
Other
annual
compensation,
consulting
fee
Securities
under
options/SARs
granted
Restricted
Shares or
restrictd
share units
LT
incentives
Michael Baghramian,
Director
-
-
-
$
3,856
-
-
-
-
-
$
-
-
Georges Benarroch,
Director
-
-
-
$
-
-
-
-
-
$
2,103
-
-
Paul Russo,
Chief executive officer, director
100,000 *
$
210,000
-
$
3,014
-
-
-
$
216,000
-
$
11,214
-
-
Jon S Saxe
Director
-
-
-
$
-
-
-
-
-
$
-
-
Peter Staple
Director
-
-
-
$
-
-
-
-
-
$
-
-
-
Simon Westbrook,
Chief financial officer
-
$
25,000
$
60,000
$
-
-
-
-
$
60,000
$
2,103
-
-
* Payment of $40,000 of this amount is deferred until Nasdaq listing
OPTION/SAR GRANTS TABLE
Name and position
Year
ended
March 31,
Options,
beginning
of year
Granted
Vested
Exercised
Options,
end of
year
Michael Baghramian, Director
-
30,000
-
-
30,000
*
30,000
157,500
-
(60,000)
127,500
Georges Benarroch, Director
-
150,000
80,959
-
150,000
*
150,000
50,000
16,592
(50,000)
150,000
Paul Russo, Chief executive officer, director
-
800,000
107,945
-
800,000
800,000
215,000
876,918
-
1,015,000
Jon S Saxe Director
-
30,000
-
30,000
*
30,000
155,000
72,726
-
185,000
Peter Staple Director
-
-
-
-
*
-
135,000
26,527
-
135,000
Simon Westbrook, Chief financial officer
-
150,000
80,959
-
150,000
150,000
50,000
182,740
-
200,000
·Mr. Saxe, Mr. Baghramian and Mr. Staple were appointed as directors as of January 1, 2021. At March 31, 2020, Mr. Saxe and Mr. Baghramian were not directors, but were granted options in their capacity as advisors to the Company.
(B) LONG-TERM INCENTIVE ("LTIP") AWARDS TABLE
None
(C) COMPENSATION OF DIRECTORS
All directors hold office until the next annual meeting of stockholders and until their successors have been duly elected and qualified. There are no agreements with respect to the election and compensation of directors. The Board of Directors appoints officers annually and each executive officer serves at the discretion of the Board of Directors.
The Company does not currently maintain insurance for the benefit of the directors and officers of Kyto against liabilities incurred by them in their capacity as directors or officers of Kyto. Kyto does not maintain a pension plan for its employees, officers or directors.
None of the directors or senior officers of Kyto and no associate of any of the directors or senior officers of Kyto was indebted to the Company during the financial period ended March 31, 2021 of Kyto other than for routine indebtedness.
(D) EMPLOYMENT CONTRACTS
Mr. Russo has an employment agreement with the Company for his service as CEO. The Agreement provides for a salary of $400,000 per annum of which 40% will be deferred until such time as the Company secures a listing on the Nasdaq exchange. Full details are incorporated by reference and are available in the employment agreement filed with the SEC in an 8K dated February 1, 2021.
(E) REPORT ON REPRICING OF OPTIONS/SARS
None

---

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
(A) SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following persons (including any group as defined in Regulation S-B, Section 228.403) are known to the Company, as the issuer, to be beneficial owner of more than five percent (5%) of any class of the said issuer's voting securities.
Title of class
Name & address of beneficial owner
Common
shares
Percentage
of class
Common
Georges Bennaroch, Florida, USA (1)
2,697,085
20.8%
Common
Paul Russo, Los Altos, California, USA
2,743,960
21.2%
(B) SECURITY OWNERSHIP OF MANAGEMENT
Title of class
Name & address of beneficial owner
Common
shares
Percentage
of class
Common
Michael Baghramian, California, USA
388,125
3.00%
Common
Georges Benarroch, Florida, USA (1)
2,697,085
20.80%
Common
Paul Russo, California, USA
2,743,960
21.20%
Common
Jon S Saxe, California , USA
150,000
1.20%
Common
Peter Staple, California, USA
90,000
0.70%
Common
Simon Westbrook, California, USA
93,750
0.70%
(1)Includes 1,781,285 shares owned by Comindus Finance Group which is controlled by Mr. Benarroch.
(C) CHANGES IN CONTROL
There is no such arrangement which may result in a change in control of the Company.

---

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
(A) CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Detail of related party transactions are described in note 3 of the accompanying Financial Statements.
There were no fees accrued or paid to directors in the years ended March 31, 2021 and 2020. At March 31, 2021 the Company had accrued and owed $46,420 accrued payroll and travel expenses to Mr. Russo and $5,000 accrued consulting fees to Mr. Westbrook, respectively. At March 31, 2020, the Company had accrued and owed $750 travel expenses to Mr. Russo and $5,000 accrued consulting fees to Mr. Westbrook, respectively.
(B) TRANSACTIONS WITH PROMOTERS
Georges Benarroch would be considered as a promoter of the Company. Georges Benarroch is the president of Comindus Finance Corp, holding 2,697,085 shares of the Company common stock represented by 20.8% of total issued and outstanding common shares.

---

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
(1) Audit Fees
RBSM LLP, Independent Registered Public Accounting firm billed an aggregate of $ 46,500 and $29,500 for audit of our annual financial statements for the fiscal years ended March 31, 2021 and 2020. These amounts include the review of our related Forms 10Q during the years audited.
(2) Audit Related Fees
No other professional services were rendered by RBSM LLP for audit related services rendered during the fiscal years ended March 31, 2021 and 2020.
(3) Tax Fees
No professional services were rendered by RBSM LLP for tax compliance, tax advice, and tax planning the fiscal years ended March 31, 2021 and 2020.

---

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
ITEM 15. EXHIBITS AND REPORTS ON FORM 10-K
(A) LISTING OF EXHIBITS
EXHIBIT
NUMBER
DESCRIPTION
3(i)(a
Articles of Incorporation of Kyto Technology and Life Science, Inc.*
3(i)(b
Articles of Amendment changing name to Kyto Technology and Life Science, Inc.*
3(ii)
Bylaws of Kyto Technology and Life Science, Inc.*
3.4
Delaware incorporation and revised articles of incorporation ***
18.1
Auditors preferability letter re adoption of ASC 946 **
31.1
Section 302 Certification of the principal executive officer and the principal financial and accounting officer
32.1
Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the principal executive officer and principal financial accounting officer
* Filed as Exhibit to Company's Form 10-SB on September 12th, 2003, with the Securities and Exchange Commission
** Filed as Exhibit with Form 10-K on July 15, 2020.
(B) Code of Ethics
Kyto Technology and Life Science, Inc. will conduct its business honestly and ethically wherever we operate in the world. We will constantly improve the quality of our services, products and operations and will create a reputation for honesty, fairness, respect, responsibility, and integrity, trust and sound business judgment. No illegal or unethical conduct on the part of officers, directors, employees or affiliates is in the company's best interest. Kyto Technology and Life Science, Inc. will not compromise its principles for short-term advantage. The ethical performance of this company is the sum of the ethics of those who work here. Thus, we are all expected to adhere to high standards of personal integrity.
Officers, directors, and employees of the company must never permit their personal interests to conflict, or appear to conflict, with the interests of the company, its clients or affiliates. Officers, directors and employees must be particularly careful to avoid representing Kyto Technology and Life Science, Inc. in any transaction with others with whom there is any outside business affiliation or relationship. Officers, directors, and employees shall avoid using their company contacts to advance their private business or personal interests at the expense of the company, its clients or affiliates.
No bribes, kickbacks or other similar remuneration or consideration shall be given to any person or organization in order to attract or influence business activity. Officers, directors and employees shall avoid gifts, gratuities, fees, bonuses or excessive entertainment, in order to attract or influence business activity.
Officers, directors and employees of Kyto Technology and Life Science, Inc. will often come into contact with, or have possession of, proprietary, confidential or business-sensitive information and must take appropriate steps to assure that such information is strictly safeguarded. This information - whether it is on behalf of our company or any of our clients or affiliates - could include strategic business plans, operating results, marketing strategies, customer lists, personnel records, upcoming acquisitions and divestitures, new investments, and manufacturing costs, processes and methods. Proprietary, confidential and sensitive business information about this company, other companies, individuals and entities should be treated with sensitivity and discretion and only be disseminated on a need-to-know basis.
Misuse of material inside information in connection with trading in the company's securities can expose an individual to civil liability and penalties. Directors, officers, and employees in possession of material information not available to the public are "insiders." Spouses, friends, suppliers, brokers, and others outside the company who may have acquired the information directly or indirectly from a director, officer or employee are also "insiders." The Act prohibits insiders from trading in, or recommending the sale or purchase of, the company's securities, while such inside information is regarded as "material," or if it is important enough to influence you or any other person in the purchase or sale of securities of any company with which we do business, which could be affected by the inside information.
The following guidelines should be followed in dealing with inside information:
Until the company has publicly released the material information, an employee must not disclose it to anyone except those within the company whose positions require use of the information.
Employees must not buy or sell the company's securities when they have knowledge of material information concerning the company until it has been disclosed to the public and the public has had sufficient time to absorb the information.
Employees shall not buy or sell securities of another corporation, the value of which is likely to be affected by an action by the company of which the employee is aware and which has not been publicly disclosed.
Officers, directors and employees will seek to report all information accurately and honestly, and as otherwise required by applicable reporting requirements.
Officers, directors and employees will refrain from gathering competitor intelligence by illegitimate means and refrain from acting on knowledge, which has been gathered in such a manner. The officers, directors and employees of Kyto Technology and Life Science, Inc. will seek to avoid exaggerating or disparaging comparisons of the services and competence of their competitors.
Officers, directors and employees will obey all Equal Employment Opportunity laws and act with respect and responsibility towards others in all of their dealings. Officers, directors and employees will remain personally balanced so that their personal life will not interfere with their ability to deliver quality products or services to the company and its clients.
Officers, directors and employees agree to disclose unethical, dishonest, fraudulent and illegal behavior, or the violation of company policies and procedures, directly to management.
Violation of this Code of Ethics can result in discipline, including possible termination. The degree of discipline relates in part to whether there was a voluntary disclosure of any ethical violation and whether or not the violator cooperated in any subsequent investigation.